aTyr Pharma Inc.

2.15+0.0350+1.66%Vol 56.75K1Y Perf -73.95%
Nov 25th, 2022 00:59 DELAYED
BID2.12 ASK2.17
Open2.12 Previous Close2.11
Pre-Market- After-Market-
 - -  - -%
Target Price
22.25 
Analyst Rating
Strong Buy 1.00
Potential %
937.30 
Finscreener Ranking
★★★★★     60.52
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★+     53.10
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★★★     58.71
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.82 
Earnings Rating
Buy
Market Cap62.22M 
Earnings Date
10th Nov 2022
Alpha-0.04 Standard Deviation0.22
Beta1.45 

Today's Price Range

2.122.15

52W Range

2.098.78

5 Year PE Ratio Range

-2.20-0.6000

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-3.38%
1 Month
-13.86%
3 Months
-39.24%
6 Months
-23.39%
1 Year
-73.95%
3 Years
-49.88%
5 Years
-96.17%
10 Years
-

TickerPriceChg.Chg.%
LIFE2.150.03501.66
AAPL148.11-2.9600-1.96
GOOG97.60-1.2200-1.23
MSFT247.49-0.0900-0.04
XOM113.21-0.4000-0.35
WFC47.440.11000.23
JNJ177.240.23000.13
FB196.640.99000.51
GE88.140.27000.31
JPM136.740.26000.19
 
ProfitabilityValueIndustryS&P 500US Markets
-
-1 476.60
-1 416.70
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.45-0.46-2.22
Q02 2022-0.43-0.44-2.33
Q01 2022-0.34-0.44-29.41
Q04 2021-0.24-0.31-29.17
Q03 2021-0.53-0.4220.75
Q02 2021-0.46-0.64-39.13
Q01 2021-0.34-0.51-50.00
Q04 2020-0.82-0.4742.68
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.472.08Positive
12/2022 FY-1.82-0.55Negative
3/2023 QR-0.550.00-
12/2023 FY-1.87-3.89Negative
Next Report Date-
Estimated EPS Next Report-0.45
Estimates Count3
EPS Growth Next 5 Years %13.00
Volume Overview
Volume56.75K
Shares Outstanding29.01K
Shares Float17.82M
Trades Count175
Dollar Volume121.10K
Avg. Volume82.10K
Avg. Weekly Volume94.45K
Avg. Monthly Volume68.69K
Avg. Quarterly Volume83.16K

aTyr Pharma Inc. (NASDAQ: LIFE) stock closed at 2.145 per share at the end of the most recent trading day (a 1.66% change compared to the prior day closing price) with a volume of 56.75K shares and market capitalization of 62.22M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 44 people. aTyr Pharma Inc. CEO is Sanjay S. Shukla.

The one-year performance of aTyr Pharma Inc. stock is -73.95%, while year-to-date (YTD) performance is -71.29%. LIFE stock has a five-year performance of -96.17%. Its 52-week range is between 2.09 and 8.78, which gives LIFE stock a 52-week price range ratio of 0.82%

aTyr Pharma Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.83, a price-to-sale (PS) ratio of 103.69, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.14%, a ROC of -45.23% and a ROE of -52.46%. The company’s profit margin is -%, its EBITDA margin is -1 416.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from aTyr Pharma Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. aTyr Pharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for aTyr Pharma Inc. is Strong Buy (1), with a target price of $22.25, which is +937.30% compared to the current price. The earnings rating for aTyr Pharma Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

aTyr Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

aTyr Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.30, ATR14 : 0.13, CCI20 : -134.97, Chaikin Money Flow : -0.23, MACD : -0.13, Money Flow Index : 35.39, ROC : -9.87, RSI : 34.87, STOCH (14,3) : 12.22, STOCH RSI : 0.26, UO : 33.69, Williams %R : -87.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of aTyr Pharma Inc. in the last 12-months were: Jill M. Broadfoot (Buy at a value of $12 980), Sanjay S. Shukla (Buy at a value of $98 376)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.25

aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.

CEO: Sanjay S. Shukla

Telephone: +1 858 731-8389

Address: 3545 John Hopkins Court, San Diego 92121, CA, US

Number of employees: 44

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

54%46%

Bearish Bullish

58%42%

Bearish Bullish

54%46%


News

Stocktwits